Royalty Revenue from Stivarga	6 Months Ended
Jun. 30, 2013
Royalty Revenue from Stivarga
Royalty Revenue from Stivarga	Note 4. Royalty Revenue from Stivarga In September 2012, Bayer HealthCare received approval in the United States for Stivarga® (regorafenib) tablets. Stivarga royalty revenue was $10.2 million and $19.3 million for the three months and six months ended June 30, 2013, respectively, or 20% of global net sales in jurisdictions that have received commercial marketing approval. In October 2011, Onyx and Bayer entered into an agreement regarding regorafenib under which the parties agreed that Bayer would pay Onyx a royalty of 20% of any future worldwide net sales in jurisdictions that have received commercial marketing approval. Onyx and Bayer also agreed that Onyx will have no obligation to pay past or future development and commercialization costs of regorafenib. Onyx has opted to co-promote regorafenib in the United States with Bayer, and to provide related medical science liaisons, under a fee-for-service arrangement, and recorded approximately $2.1 million and $3.7 million during the three months and six months ended June 30, 2013, respectively, which was classified net of selling, general and administrative expense on the Consolidated Statements of Operations. Development of regorafenib is managed by the same joint governance bodies that manage development of Nexavar; however, in the event of disagreement Bayer has the right to make final decisions for regorafenib.

Note 4. Royalty Revenue from Stivarga

In September 2012, Bayer HealthCare received approval in the United States for Stivarga® (regorafenib) tablets. Stivarga royalty revenue was $10.2 million and $19.3 million for the three months and six months ended June 30, 2013, respectively, or 20% of global net sales in jurisdictions that have received commercial marketing approval. In October 2011, Onyx and Bayer entered into an agreement regarding regorafenib under which the parties agreed that Bayer would pay Onyx a royalty of 20% of any future worldwide net sales in jurisdictions that have received commercial marketing approval. Onyx and Bayer also agreed that Onyx will have no obligation to pay past or future development and commercialization costs of regorafenib. Onyx has opted to co-promote regorafenib in the United States with Bayer, and to provide related medical science liaisons, under a fee-for-service arrangement, and recorded approximately $2.1 million and $3.7 million during the three months and six months ended June 30, 2013, respectively, which was classified net of selling, general and administrative expense on the Consolidated Statements of Operations. Development of regorafenib is managed by the same joint governance bodies that manage development of Nexavar; however, in the event of disagreement Bayer has the right to make final decisions for regorafenib.